Bayer posts 10.2% net income growth

Bayer has reported net income of €4,531 million which is 10.2% increase comparing to 2015 (€4,110 million). The company reported earnings growth in pharmaceutical activities, while other activities remain steady.

The company has reported key growth in its five leading pharmaceutical products: oral anticoagulant Xarelto, the eye medicine Eylea, the cancer drugs Xofigo and Stivarga, and the pulmonary hypertension treatment Adempas posted total combined sales of EUR 5,413 million (2015: EUR 4,231 million).

“Sales at Pharmaceuticals advanced by a gratifying amount. We expanded business markedly in all regions,” said Management Board Chairman Werner Baumann.



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.